Management of Patient with >20% Blast Cells

Diagnostic Evaluation

The National Comprehensive Cancer Network recommends a comprehensive diagnostic workup, including complete blood count with differential, platelet count, and comprehensive metabolic panel, to assess baseline organ function and cytopenias in patients with >20% blast cells 1, 3, 4
Coagulation studies, such as PT, PTT, and fibrinogen, should be performed before any invasive procedures, as coagulopathy is common at presentation 3
Bone marrow aspiration and biopsy with cytogenetics are mandatory to identify prognostic chromosomal abnormalities 1, 2, 4
Immunophenotyping by flow cytometry is essential to confirm myeloid lineage and establish a baseline for minimal residual disease monitoring 1, 2, 3
Molecular testing for FLT3-ITD, NPM1, and CEBPA mutations provides critical prognostic information and guides therapeutic decisions 1, 2, 4

The National Comprehensive Cancer Network recommends HLA typing of patients and siblings for all patients who are potential allogeneic hematopoietic stem cell transplant (HSCT) candidates, except those with major contraindications 1, 3, 4
Initiate unrelated donor search early for patients with poor-risk features who lack a sibling donor, ideally during induction chemotherapy rather than waiting for remission 3
Favorable-risk cytogenetics, such as t(8;21), inv(16), and t(15;17), are associated with a better prognosis, and standard chemotherapy with consideration for consolidation is recommended 1, 3
Intermediate-risk disease, defined as a normal karyotype, requires molecular markers, such as FLT3, NPM1, and CEBPA, to determine whether HSCT is recommended in first remission 1, 2
Poor-risk features, including complex karyotype, monosomal karyotype, and therapy-related AML, require early HSCT planning 1, 3

Cardiac evaluation, such as echocardiogram or MUGA scan, is recommended for patients with prior cardiac history, prior anthracycline exposure, cardiotoxic drug exposure planned, or cardiac symptoms 1, 3, 4
CNS imaging, such as CT or MRI, is recommended if neurologic symptoms are present, followed by lumbar puncture if no mass lesion is detected 1, 4
Screening lumbar puncture at first remission is recommended for high-risk patients, including those with monocytic differentiation, WBC >40,000-100,000/mcL, or extramedullary disease 3